![Frontiers | A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy | Immunology Frontiers | A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy | Immunology](https://www.frontiersin.org/files/Articles/707211/fimmu-12-707211-HTML-r1/image_m/fimmu-12-707211-g001.jpg)
Frontiers | A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy | Immunology
![New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype | Clinical Cancer Research New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype | Clinical Cancer Research](https://clincancerres.aacrjournals.org/content/clincanres/21/21/4753/F1.large.jpg)
New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype | Clinical Cancer Research
![Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma - ScienceDirect Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1525001616335997-gr1.jpg)
Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma - ScienceDirect
![Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial - The Lancet Oncology Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fed8c7ab-63f7-4478-bc18-ce99956742dd/gr1.gif)
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial - The Lancet Oncology
![Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-019-0756-z/MediaObjects/13045_2019_756_Fig1_HTML.png)
Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text
![Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety | Experimental & Molecular Medicine Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety | Experimental & Molecular Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs12276-019-0221-7/MediaObjects/12276_2019_221_Fig1_HTML.png)
Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety | Experimental & Molecular Medicine
![Ewing Sarcoma and Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue Treatment (PDQ®)–Health Professional Version - National Cancer Institute Ewing Sarcoma and Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue Treatment (PDQ®)–Health Professional Version - National Cancer Institute](https://nci-media.cancer.gov/pdq/media/images/777901.jpg)
Ewing Sarcoma and Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue Treatment (PDQ®)–Health Professional Version - National Cancer Institute
![Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/2/e001580/F1.large.jpg)
Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer
![References in Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications - Cancer Treatment Reviews References in Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3609e4eb-98ce-4f15-aead-bcd7844dad0e/gr1_lrg.jpg)
References in Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications - Cancer Treatment Reviews
![Frontiers | Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment | Oncology Frontiers | Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment | Oncology](https://www.frontiersin.org/files/Articles/581107/fonc-10-581107-HTML-r1/image_m/fonc-10-581107-g001.jpg)
Frontiers | Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment | Oncology
![Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies | SpringerLink Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10555-019-09839-9/MediaObjects/10555_2019_9839_Figa_HTML.png)